Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarification sought from Sun Pharmaceutical Industries Ltd

 The Exchange has sough Clarification from Sun Pharmaceutical Industries Ltd with reference to the media report appearing on https://economictimes.indiatimes.com dated January 14, 2023 (Link:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-pulls-up-sun-pharma-for-lapses-in-halol-plant/articleshow/96983600.cms) titled "USFDA pulls up Sun Pharma for lapses in Halol plant"The reply is awaited.
16-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Investor Presentation

 SPIL Investor Presentation
16-01-2023

Sun Pharma pulled up by USFDA for lapses in Halol plant

 USFDA pointed out various lapses at the Sun Pharma's Halol plant which produces finished pharmaceutical products.
14-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
12-01-2023

Sun Pharmaceuticals launches drug for advanced breast cancer patients

 Sun Pharmaceutical on Wednesday launched a novel anti-cancer drug Palbociclib under the brand name of Palenotm for patients with advanced breast cancer.
11-01-2023

Jefferies sees big pharma firms getting bigger, lists Sun Pharma, Syngene as top picks

 The USD 27 billion domestic pharma industry has structural growth drivers in place and well-placed to achieve low double-digit growth in the coming years.
11-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release on launch of a novel anti-cancer drug, Palbociclib in India.
11-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Submission of Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2022
10-01-2023

Top Indian pharma stocks to buy/hold: BNP Paribas shares preferred picks

 Sun Pharma remains its top stock pick, followed by JB Chemicals and Pharma (JBCP)
10-01-2023
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
07-01-2023
Next Page
Close

Let's Open Free Demat Account